GlassScriptPhysician profile
Conrad B Cox
NPI 1346629243
$4,234.35
in general payments reported to CMS, 2019-2025
24 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 85% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $363 · 2022: $813 · 2023: $621 · 2024: $625 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374 · Travel and Lodging: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.61 |
| Travel and Lodging | $559.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,363.95 | 2025 | |
| Abbvie INC. | $590.62 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $308.34 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $291.52 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $267.47 | 2022-2024 | |
| Janssen Biotech, INC. | $214.02 | 2021-2025 | Stelara, Remicade, Simponi |
| Alcresta Therapeutics, INC. | $188.41 | 2023-2024 | Relizorb |
| Nestle Healthcare Nutrition INC. | $160.10 | 2021-2023 | |
| Endogastric Solutions, INC | $153.73 | 2022-2023 | Esophyx |
| Medtronic, INC. | $146.90 | 2021-2024 | Interstim |
| Mirum Pharmaceuticals, INC. | $135.92 | 2022-2025 | Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $62.88 | 2022-2024 | Eohilia |
| Phadia US INC. | $54.25 | 2024-2025 | Immunocap |
| Albireo Pharma, INC. | $52.89 | 2022-2023 | Bylvay |
| Sandoz INC. | $46.99 | 2023-2024 | Hyrimoz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $35.63 | 2021 | |
| Organon LLC | $34.16 | 2024 | |
| Lnhc, INC | $22.04 | 2025 | Zelsuvmi |
| Madrigal Pharmaceuticals | $21.91 | 2024 | Resmetirom |
| Travere Therapeutics, INC. | $20.80 | 2021 | |
| Gilead Sciences, INC. | $19.98 | 2022 | |
| Kaleo, INC. | $15.45 | 2022 | |
| Coloplast Corp | $14.40 | 2025 | |
| Vivus LLC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.